Reneo Pharmaceuticals (RPHM) Stock Forecast & Price Target

$1.51

+0.01 (+0.67%)

(As of 09/19/2024 ET)

Reneo Pharmaceuticals - Analysts' Recommendations and Stock Price Forecast (2024)

MarketBeat calculates consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0 to .5 = Strong Sell, .5 to 1 = Sell, 1 to 1.5 = Reduce, 1.5 to 2.5 = Hold, 2.5 to 3.0 = Moderate Buy, 3.0 to 3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.

Consensus Rating

Reduce
Based on 8 Analyst Ratings

Based on 8 Wall Street analysts who have issued ratings for Reneo Pharmaceuticals in the last 12 months, the stock has a consensus rating of "Reduce." Out of the 8 analysts, 1 has given a sell rating, and 7 have given a hold rating for RPHM.

Consensus Price Target

$11.01
629.30% Upside

High Forecast	$35.55
Average Forecast	$11.01
Low Forecast	$1.50

According to the 8 analysts' twelve-month price targets for Reneo Pharmaceuticals, the average price target is $11.01. The highest price target for RPHM is $35.55, while the lowest price target for RPHM is $1.50. The average price target represents a forecasted upside of 629.30% from the current price of $1.51.

Type	Current Forecast 9/20/23 to 9/19/24	1 Month Ago 8/21/23 to 8/20/24	3 Months Ago 6/22/23 to 6/21/24	1 Year Ago 9/20/22 to 9/20/23
Consensus Rating	Reduce	Reduce	Reduce	Buy
Strong Buy	0 Strong Buy rating(s)	0 Strong Buy rating(s)	0 Strong Buy rating(s)	0 Strong Buy rating(s)
Buy	0 Buy rating(s)	0 Buy rating(s)	0 Buy rating(s)	2 Buy rating(s)
Hold	7 Hold rating(s)	7 Hold rating(s)	7 Hold rating(s)	0 Hold rating(s)
Sell	1 Sell rating(s)	1 Sell rating(s)	1 Sell rating(s)	0 Sell rating(s)
Consensus Price Target	$11.01	$11.01	$11.01	$30.00
Forecasted Upside	629.30% Upside	445.95% Upside	445.95% Upside	308.72% Upside

Get Reneo Pharmaceuticals Upgrade and Downgrade Alerts

Sign-up to receive the latest news and ratings for RPHM and its competitors with MarketBeat's FREE daily newsletter.

War on Elon Escalates… (Ad)

Elon Musk, the guy slated to become the world’s first trillionaire by 2027, has publicly called for the adoption of this technology for decades. By doing so he has put himself in the crosshairs of an ideological war with the global elites. And yet, while this new technology threatens their wealth and power, it could be transformational for both the U.S. economy and your wealth.

Click here to learn how you can benefit from its widespread distribution.

RPHM Analyst Recommendations By Month

The chart below shows how a company's ratings by analysts have changed over time. Each bar represents the previous year of ratings for that month. Within each bar, the sell ratings are shown in red, the hold ratings are shown in yellow, the buy ratings are shown in green, and the strong buy ratings are shown in dark green.

RPHM Price Targets by Month

The chart below shows how a company's share price and consensus price target have changed over time. The dark blue line represents the company's actual price. The lighter blue line represents the stock's consensus price target. The even lighter blue range in the background of the two lines represents the low price target and the high price target for each stock.

Reneo Pharmaceuticals Stock vs. The Competition

Type	Reneo Pharmaceuticals	Medical Companies	S&P 500
Consensus Rating Score	1.88	2.77	2.50
Consensus Rating	Reduce	Moderate Buy	Moderate Buy
Predicted Upside	659.48% Upside	994.77% Upside	6.53% Upside
News Sentiment Rating	Neutral News	Neutral News	Positive News

Recent Analyst Forecasts and Stock Ratings

Rating

Upside/Downside

Action

Time Frame

Start Date

End Date

Show

Export to Excel

Date	Brokerage	Analyst Name	Action	Rating	Price Target	Upside/Downside on Report Date
5/14/2024	HC Wainwright 2 of 5 stars	M. Kapoor Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Neutral ➝ Neutral	$1.50	-5.66%
12/15/2023	Leerink Partners 1 of 5 stars		Reiterated Rating	Outperform ➝ Market Perform
12/15/2023	Jefferies Financial Group 2 of 5 stars		Reiterated Rating	Buy ➝ Hold
12/14/2023	LADENBURG THALM/SH SH Subscribe to MarketBeat All Access for the recommendation accuracy rating		Downgrade	Buy ➝ Neutral
12/14/2023	Bank of America Subscribe to MarketBeat All Access for the recommendation accuracy rating		Downgrade	Buy ➝ Underperform
12/14/2023	William Blair Subscribe to MarketBeat All Access for the recommendation accuracy rating	M. Minter Subscribe to MarketBeat All Access for the recommendation accuracy rating	Downgrade	Outperform ➝ Market Perform
12/14/2023	Piper Sandler Subscribe to MarketBeat All Access for the recommendation accuracy rating		Downgrade	Overweight ➝ Neutral	$25.00 ➝ $4.00	+247.82%
12/14/2023	Robert W. Baird Subscribe to MarketBeat All Access for the recommendation accuracy rating		Downgrade	Outperform ➝ Neutral	$28.00 ➝ $3.00	+160.87%

Analyst ratings data on MarketBeat is provided by Benzinga and other data providers. This page was last refreshed on Thursday at 10:53 PM ET.

RPHM Forecast - Frequently Asked Questions

What is Reneo Pharmaceuticals' forecast for 2024?: According to the research reports of 8 Wall Street equities research analysts, the average twelve-month stock price forecast for Reneo Pharmaceuticals is $11.01, with a high forecast of $35.55 and a low forecast of $1.50.
Should I buy or sell Reneo Pharmaceuticals stock right now?: 8 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Reneo Pharmaceuticals in the last twelve months. There is currently 1 sell rating and 7 hold ratings for the stock. The consensus among Wall Street analysts is that investors should "reduce" RPHM shares.
Does Reneo Pharmaceuticals's stock price have much upside?: According to analysts, Reneo Pharmaceuticals's stock has a predicted upside of 445.95% based on their 12-month stock forecasts.
Do Wall Street analysts like Reneo Pharmaceuticals more than its competitors?: Analysts like Reneo Pharmaceuticals less than other "medical" companies. The consensus rating for Reneo Pharmaceuticals is Reduce while the average consensus rating for "medical" companies is Moderate Buy. Learn more on how RPHM compares to other companies.